CN1456168A - Anti-fatigue formulating prescription - Google Patents
Anti-fatigue formulating prescription Download PDFInfo
- Publication number
- CN1456168A CN1456168A CN03120760.XA CN03120760A CN1456168A CN 1456168 A CN1456168 A CN 1456168A CN 03120760 A CN03120760 A CN 03120760A CN 1456168 A CN1456168 A CN 1456168A
- Authority
- CN
- China
- Prior art keywords
- prescription
- fatigue
- improving
- pueraria root
- root extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 8
- 229930064664 L-arginine Natural products 0.000 claims abstract description 8
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 7
- 230000037080 exercise endurance Effects 0.000 claims abstract description 6
- 230000004202 respiratory function Effects 0.000 claims abstract description 5
- 241000219780 Pueraria Species 0.000 claims description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000000141 anti-hypoxic effect Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000011362 coarse particle Substances 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 abstract description 9
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 7
- 241000219781 Pueraria montana var. lobata Species 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 229930003935 flavonoid Natural products 0.000 abstract description 5
- 150000002215 flavonoids Chemical class 0.000 abstract description 5
- 235000017173 flavonoids Nutrition 0.000 abstract description 5
- 238000009825 accumulation Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 239000003963 antioxidant agent Substances 0.000 abstract description 3
- 230000003078 antioxidant effect Effects 0.000 abstract description 3
- 210000000170 cell membrane Anatomy 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 abstract description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 abstract description 2
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000003834 intracellular effect Effects 0.000 abstract description 2
- 239000002207 metabolite Substances 0.000 abstract description 2
- 230000026731 phosphorylation Effects 0.000 abstract description 2
- 238000006366 phosphorylation reaction Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 239000000758 substrate Substances 0.000 abstract description 2
- 150000003254 radicals Chemical class 0.000 description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- -1 ethyl acetate Ester Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000518 sarcolemma Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种抗疲劳、提高运动耐力的组方及产品生产方法。其特征在于：组方由葛根提取物—葛根总黄酮与L－精氨酸以0.5～1.5∶1的比例组成，该组方能够改善呼吸功能和血液循环功能、提高血液抗氧化能力、减少酸性代谢产物产生和蓄积、减少细胞内酶的释放入血，还可使血液碱性磷酸酶活性明显提高，有利于底物水平磷酸化，促进有氧代谢和保护细胞膜，可作为保健品或药物做成多种制剂用于抗疲劳、提高运动耐力及改善呼吸功能。The invention relates to a prescription for anti-fatigue and improving exercise endurance and a production method for the product. It is characterized in that: the prescription is composed of kudzu root extract-total flavonoids of kudzu root and L-arginine in a ratio of 0.5 to 1.5:1, and the prescription can improve respiratory function and blood circulation function, improve blood antioxidant capacity, and reduce acidity The production and accumulation of metabolites, reducing the release of intracellular enzymes into the blood, can also significantly increase the activity of alkaline phosphatase in the blood, which is conducive to the phosphorylation of substrate levels, promotes aerobic metabolism and protects cell membranes. It can be used as health care products or medicines It is used in various preparations for anti-fatigue, improving exercise endurance and improving respiratory function.
Description
本发明涉及一种组方，其特点在于它由L-精氨酸与葛根或葛根提取成分两种原料组成，其比例为0.5～1∶2(L-精氨酸∶葛根或葛根提取成分)，该组方通过改善呼吸功能，提高抗缺氧能力的科学组方而发挥抗疲劳功效、提高运动耐力的作用。The invention relates to a prescription, which is characterized in that it is composed of L-arginine and kudzu root or kudzu root extract components, and the ratio is 0.5-1:2 (L-arginine: kudzu root or kudzu root extract components) , the formula can exert anti-fatigue effect and improve exercise endurance through the scientific formula of improving respiratory function and anti-hypoxic ability.
根据自由基生物医学理论，正常生理条件下，机体内自由基的产生与清除处于动态平衡中，而急性运动则会破坏这种平衡，导致自由基的堆积。Davis(1982)首先用电子自旋共振技术研究发现大鼠在跑台上进行亚极量运动至力竭时，自由基的产生率增多2-3倍。研究表明，急性运动引起的自由基水平增高及脂质过氧化加强会导致肌纤维膜及线粒体膜等生物膜完整性丧失及损伤，从而损害线粒体并引发一系列细胞代谢机能紊乱，细胞广泛性损害及病理变化，最终导致肌肉工作能力下降，出现运动性疲劳。另一方面，根据生物代谢机制，生物体内有两种代谢，即有氧代谢和无氧代谢。在高强度运动时，由于机体处于一定程度的缺氧状态，无氧代谢占一定比例，无氧代谢时产生的大量自由基与乳酸所导致机体内环境稳态失调是引起运动性疲劳的重要原因，故改善利用氧的能力和心血管系统的供氧能力，使有氧代谢能力增强，减少体内乳酸的堆积，以维持内环境酸碱平衡的稳态具有重要意义。但迄今为止，能够针对性改善机体缺氧环境、提高抗疲劳能力、安全有效的功能性运动补剂仍然很少，并且一些具有提高耐力的固醇类药物具有很强的副作用。因此，应该从天然食物或中草药中选取有效成分，根据它们的药理特点选择合理的药物组方，加工成方便的制剂，发挥预期疗效。According to the biomedical theory of free radicals, under normal physiological conditions, the production and removal of free radicals in the body are in a dynamic balance, but acute exercise will destroy this balance, resulting in the accumulation of free radicals. Davis (1982) first used electron spin resonance technology to study and found that when rats performed submaximal exercise on the treadmill to exhaustion, the production rate of free radicals increased by 2-3 times. Studies have shown that the increased level of free radicals and enhanced lipid peroxidation caused by acute exercise will lead to the loss and damage of biological membranes such as sarcolemma and mitochondrial membranes, thereby damaging mitochondria and causing a series of cellular metabolic disorders, extensive cell damage and Pathological changes will eventually lead to a decrease in muscle working ability and exercise-induced fatigue. On the other hand, according to the mechanism of biological metabolism, there are two kinds of metabolism in organisms, namely, aerobic metabolism and anaerobic metabolism. During high-intensity exercise, because the body is in a state of hypoxia to a certain extent, anaerobic metabolism accounts for a certain proportion. The large amount of free radicals and lactic acid produced during anaerobic metabolism lead to the imbalance of the body's internal environment homeostasis, which is an important cause of exercise-induced fatigue. Therefore, it is of great significance to improve the ability to utilize oxygen and the oxygen supply capacity of the cardiovascular system, enhance aerobic metabolism, reduce the accumulation of lactic acid in the body, and maintain the steady state of the acid-base balance in the internal environment. But so far, there are still few safe and effective functional sports supplements that can specifically improve the hypoxic environment of the body, improve the anti-fatigue ability, and some steroid drugs that can improve endurance have strong side effects. Therefore, active ingredients should be selected from natural foods or Chinese herbal medicines, and reasonable drug prescriptions should be selected according to their pharmacological characteristics, and processed into convenient preparations to exert the expected curative effect.
本发明的目的是为了提供一种具有提高运动耐力的产品。它可用于运动员、军人及普通百姓。它主要是根据L-精氨酸与中药成分葛根总黄酮的药理特点，研究表明葛根总黄酮是一种良好的抗氧化剂，能有效的清除多种自由基、阻断细胞膜脂质过氧化反应从而减轻自由基对生物膜的损害，葛根总黄酮的结构决定了它具有抗炎、抗疲劳作用。L-精氨酸是产生N0的前体或供体，近年来的研究表明，它可能通过提高内源性NO含量起到舒张气道及心血管平滑肌，增加肺活量，从而提高抗机体耐缺氧的能力。该组方通过改善呼吸功能和血液循环功能、提高血液抗氧化能力、减少酸性代谢产物产生和蓄积、细胞内酶(CK、LDH、GPT、GOT)的释放、提高血液碱性磷酸酶活性使之有利于底物水平磷酸化，促进有氧代谢和保护细胞膜而达到提高运动耐力的目的。The purpose of the present invention is to provide a product capable of improving exercise endurance. It can be used by athletes, soldiers and ordinary people. It is mainly based on the pharmacological characteristics of L-arginine and total flavonoids of Pueraria radiata, a traditional Chinese medicine ingredient. Studies have shown that total flavonoids of Pueraria radiata is a good antioxidant, which can effectively scavenge a variety of free radicals, block lipid peroxidation of cell membranes and thus Reduce the damage of free radicals to the biofilm. The structure of the total flavonoids of Pueraria radiata determines that it has anti-inflammatory and anti-fatigue effects. L-arginine is the precursor or donor of NO production. Recent studies have shown that it may relax the airway and cardiovascular smooth muscle by increasing the content of endogenous NO, increase lung capacity, and thus improve the body's resistance to hypoxia. Ability. This formula improves respiratory function and blood circulation function, improves blood antioxidant capacity, reduces the production and accumulation of acidic metabolites, releases intracellular enzymes (CK, LDH, GPT, GOT), and increases blood alkaline phosphatase activity to make it It is beneficial to the phosphorylation of the substrate level, promotes aerobic metabolism and protects the cell membrane to achieve the purpose of improving exercise endurance.
本发明是这样实现的：以自由基生物医学为指导，利用现代科学提取技术从天然植物中通过大量提取、筛选，以及对现有研究成果的科学分析，将葛根提取物和L-精氨酸按一定比例混合而制成胶囊、冲剂、口服液、片剂和饮料等多种剂型。The present invention is achieved in this way: guided by free radical biomedicine, using modern scientific extraction technology from natural plants through a large number of extraction, screening, and scientific analysis of existing research results, Pueraria root extract and L-arginine Mix according to a certain ratio to make various dosage forms such as capsules, granules, oral liquids, tablets and beverages.
本发明公布葛根总黄酮的提取工艺：葛根饮片、粗颗粒或粉末经70-95％乙醇减压回流提取1-3小时，过滤，重复3次，回收乙醇后，加蒸馏水稀释，再用乙酸乙酯提取，回收后即得葛根素含量为39.8％的葛根提取物。The invention discloses the extraction process of the total flavonoids of Pueraria lobata: Pueraria decoction pieces, coarse particles or powder are extracted by reflux of 70-95% ethanol under reduced pressure for 1-3 hours, filtered, and repeated 3 times. After recovering ethanol, add distilled water to dilute, and then use ethyl acetate Ester extraction, after recovery, the Pueraria root extract with a puerarin content of 39.8% was obtained.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB03120760XA CN100455292C (en) | 2003-03-19 | 2003-03-19 | A new type of anti-fatigue formula |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB03120760XA CN100455292C (en) | 2003-03-19 | 2003-03-19 | A new type of anti-fatigue formula |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1456168A true CN1456168A (en) | 2003-11-19 |
| CN100455292C CN100455292C (en) | 2009-01-28 |
Family
ID=29411565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB03120760XA Expired - Fee Related CN100455292C (en) | 2003-03-19 | 2003-03-19 | A new type of anti-fatigue formula |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100455292C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101336723B (en) * | 2008-07-30 | 2012-07-18 | 广州蓝钥匙海洋生物工程有限公司 | Health food for relieving physical fatigue |
-
2003
- 2003-03-19 CN CNB03120760XA patent/CN100455292C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101336723B (en) * | 2008-07-30 | 2012-07-18 | 广州蓝钥匙海洋生物工程有限公司 | Health food for relieving physical fatigue |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100455292C (en) | 2009-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101401830B (en) | Preparation method for extracting flavone from purslane and uses thereof | |
| CN1840166A (en) | Wendan decoction modern traditional Chinese medicine oral preparation and production method thereof | |
| CN1951222B (en) | A health food for relieving fatigue and preparation method thereof | |
| CN104997883A (en) | Inonotus obliquus raspberry tree red raspberry composition, inonotus obliquus raspberry tree red raspberry composite oral solution and preparation method and application thereof | |
| CN109432387A (en) | It is a kind of with the Chinese medicine-peptide combinations and preparation method thereof for resisting drunk effect | |
| CN102579836B (en) | Traditional Chinese medical dendrobium huoshanense composition and preparation method thereof | |
| CN102551046B (en) | Natural health composition for weight reduction and application of same | |
| CN117137141A (en) | A composition that resists exercise fatigue and improves hypoxic tolerance and its application | |
| CN103393097A (en) | Health food with effects of sobering and protecting liver | |
| CN102784230B (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| CN116138455A (en) | Panax notoginseng polysaccharide extract and its application in the preparation of anti-fatigue products | |
| CN105250989A (en) | Donkey-hide glue small peptide composition for resisting fatigue | |
| CN1456168A (en) | Anti-fatigue formulating prescription | |
| CN100345566C (en) | Medicine composition used for reducing weight, prepn. method and use thereof | |
| CN107242563A (en) | A kind of fatigue resistant health food and preparation method thereof | |
| CN104435349B (en) | Composition with facilitating alcohol metabolism and protecting liver effect and its preparation method and application | |
| CN101889683A (en) | A kind of health food with anti-fatigue function and preparation method thereof | |
| CN1115159C (en) | Red sage containing medicine composition and its preparation and use | |
| CN101810264B (en) | Health-care food having auxiliary blood pressure reduction effect and method for preparing same | |
| CN116849357B (en) | Medicinal and edible composition with liver protection function and preparation method thereof | |
| CN102631486B (en) | Health care composition | |
| KR102661871B1 (en) | A beverage composition for preventing or improving hangover | |
| KR20190069904A (en) | Tablet-type composition for preventing and relieving hangover, and protecting hepatic caused by alcohol containing medical herbs | |
| CN110064023B (en) | Anti-fatigue traditional Chinese medicine product and preparation method thereof | |
| CN100566598C (en) | A health product containing bamboo tire powder for improving anemia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: SONG SHUZHEN Effective date: 20030708 Owner name: GENERAL HOSPITAL OF P.L.A. Free format text: FORMER OWNER: TIAN YAPING |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20030708 Address after: 100853, Fuxing Road, Beijing, No. 16, building 4, No. 28, gate 302 Applicant after: General Hospital of Chinese PLA Address before: 100853, Fuxing Road, Beijing, No. 16, building 4, No. 28, gate 302 Applicant before: Tian Yaping Co-applicant before: Song Shuzhen |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090128 Termination date: 20130319 |